Clinical trials: Chronic Myeloid Leukemia (CML)
Leukemia
Topotecan in Treating Children With Refractory Leukemia
Phase I trial to study the effectiveness of topotecan in treating children with refractory leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00002705
- Testing
- topotecan hydrochloride
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)
This study will evaluate MK0457 in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be evaluated.
- Trial name
- NCT00405054
- Testing
- MK0457
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Myeloid Leukemia
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
This is a efficacy and safety study of imatinib Mesylate Capsule as First line treatment in patients with chronic phase of Chronic Myeloid Leukemia.
- Trial name
- NCT02317159
- Testing
- Imatinib
- Volunteers
- 90 people
- Sponsor
- Cttq
Chronic Myeloid Leukemia
CML Pediatric ITK Response According to Molecular Identification at Diagnosis
Treatment of chronic myeloid leukemia (CML) has been revolutionized by tyrosine kinase inhibitor (TKI). Nevertheless, case of failure and suboptimal response are still observed even in children.
- Trial name
- CML Piramid (NCT05605379)
- Testing
- Next Generation Sequencing (DNA and RNA)
- Where
- France
- Volunteers
- 88 people
- Sponsor
- University Hospital, Bordeaux
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of abnormal and cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00346359
- Testing
- anti-thymocyte globulin, busulfan, fludarabine phosphate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloid Leukemia
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.
- Trial name
- NCT07269470
- Testing
- Dasatinib, Ropeginterferon alfa-2b (P1101)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
CML, Chronic Phase
Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.
- Trial name
- ICT10 (NCT02949570)
- Testing
- Inecalcitol
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Hybrigenics Corporation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase…
- Trial name
- NCT00171223
- Testing
- STI571
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 532 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia
Patients with leukemia often have low white blood cell counts after chemotherapy, which puts them at greater risk for infection.
- Trial name
- NCT01204788
- Testing
- Prophylactic White Cell Transfusion, Therapeutic White Cell Transfusion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia in Chronic Phase
Managed Access Programs for ABL001, Asciminib
The purpose of this registration form is to list all Managed Access Programs (MAPs) related to ABL001, asciminib
- Trial name
- NCT04360005
- Testing
- Asciminib
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumor
Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions
To characterize pharmacokinetic profile of test product compared to that of the corresponding reference product in adult patients, who are diagnosed to have Chronic Myeloid Leukemia \& Gastrointestinal Stromal Tumor under Fed…
- Trial name
- NCT02103322
- Testing
- Imatinib Mesylate Tablets, 400 mg
- Where
- 5 sites in India
- Volunteers
- 48 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Chronic Myeloid Leukemia
Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia
It's an observational study based on 98 patients included in the STIM trial to extend the monitoring of patients and to have molecular and clinical data, with long follow up.
- Trial name
- STIM-FU (NCT02896829)
- Testing
- Interruption of the treatment by Imatinib
- Where
- 19 sites in France
- Volunteers
- 97 people
- Sponsor
- University Hospital, Bordeaux
Malignancy, Hematologic, Neoplasms, Hematologic
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes.
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
- Trial name
- NCT06904066
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
The goal of this clinical research study is to find the highest safe dose of Mylotarg that can be combined with chemotherapy in patients receiving allogeneic bone marrow transplantation.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia
- Trial name
- NCT00038831
- Testing
- Mylotarg, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
This phase II trial studies the side effects and best dose of total-body irradiation when given together with fludarabine phosphate followed by a donor peripheral stem cell transplant in treating patients with myelodysplastic…
- Conditions
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia
- Trial name
- NCT00397813
- Testing
- Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
AML, Advanced MDS
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
The purpose of Phase I of this study is to test the safety and tolerability of the investigational drug, OTS167, and that of Phase II of this study is to confirm the potential response benefit of OTS167.
- Conditions
- AML, Advanced MDS, ALL, Advanced CML
- Trial name
- NCT02795520
- Testing
- OTS167IV
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- OncoTherapy Science, Inc.
Chronic Myeloid Leukemia
Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia
Nilotinib vs imatinib in patients with newly diagnosed CML-CP
- Trial name
- NCT03228303
- Testing
- Nilotinib 150 MG [Tasigna], Imatinib 400mg
- Volunteers
- 100 people
- Sponsor
- Assiut University
Chronic Myelogenous Leukemia
TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients
The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had…
- Trial name
- NCT06088888
- Testing
- TGRX-678
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Chronic Myelogenous Leukemia
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
The leukemic stem cells (LSCs) are cells that self- renew and give rise to leukemia. Eradication of LSC is required for cure. In chronic myelogenous leukemia (CML) LSCs are not eradicated by imatinib (Gleevec) alone.
- Trial name
- NCT01130688
- Testing
- Zileuton
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Massachusetts, Worcester
Chronic Myeloid Leukemia
Reduced Intensity AlloSCT in(CML) With Persistent Disease
CML, a malignant disorder of stem cells, is characterized by increases in both immature and mature myeloid, erythroid, and lymphoid cells, as well as platelets in the peripheral blood.
- Trial name
- CML (NCT00531310)
- Testing
- Reduced Intensity Conditioning, Busulfan and Fludarabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.